96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects (Q41428068)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 January 2015

Language	Label	Description	Also known as
English	96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects	scientific article published on 21 January 2015

Statements

scholarly article

1 reference

Europe PubMed Central

30 September 2017

96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects (English)

1 reference

Europe PubMed Central

30 September 2017

anti-retroviral agent

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Danielle P Porter

1

object named as

Danielle P Porter

1 reference

Europe PubMed Central

30 September 2017

author name string

Rima Kulkarni

2

1 reference

Europe PubMed Central

30 September 2017

Todd Fralich

3

1 reference

Europe PubMed Central

30 September 2017

Michael D Miller

4

1 reference

Europe PubMed Central

30 September 2017

Kirsten L White

5

1 reference

Europe PubMed Central

30 September 2017

publication date

21 January 2015

1 reference

Europe PubMed Central

30 September 2017

HIV Clinical Trials

1 reference

Europe PubMed Central

30 September 2017

16

1 reference

Europe PubMed Central

30 September 2017

30-38

1 reference

Europe PubMed Central

30 September 2017

1

1 reference

Europe PubMed Central

30 September 2017

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

A decade of HIV-1 drug resistance in the United States: trends and characteristics in a large protease/reverse transcriptase and co-receptor tropism database from 2003 to 2012.

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Identifiers

10.1179/1528433614Z.0000000009

1 reference

Europe PubMed Central

30 September 2017

1 reference

Europe PubMed Central

30 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41428068&oldid=2147111451"